CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Ironwood
Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host
its second quarter 2012 investor update conference call and webcast at
8:30 a.m. Eastern Time on Tuesday, July 17, 2012. Individuals interested
in participating in the call should dial (877) 643-7155 (U.S. and
Canada) or (914) 495-8552 (international) using conference ID number
98056073. To access the webcast, please visit the Investors section of
Ironwood's website at www.ironwoodpharma.com
at least 15 minutes prior to the start of the call to ensure adequate
time for any software downloads that may be required.
The call will be available for replay via telephone starting July 17,
2012 at approximately 11:30 a.m. Eastern Time, running through 11:59
p.m. Eastern Time on July 31, 2012. To listen to the replay, dial (855)
859-2056 (U.S. and Canada) or (404) 537-3406 (international) using
conference ID number 98056073. The archived webcast will be available on
Ironwood's website for 14 days beginning approximately one hour after
the call.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial
pharmaceutical company dedicated to the art and science of great
drugmaking. Linaclotide, Ironwood's guanylate cyclase-C agonist (GCCA),
is an investigational drug for the treatment of irritable bowel syndrome
with constipation (IBS-C) and chronic constipation. The efficacy portion
of linaclotide's development program has been completed and supports the
submitted NDA for both indications, as well as the MAA submission in
Europe for the IBS-C indication. Ironwood also has a growing pipeline of
additional drug candidates in earlier stages of development. Ironwood is
located in Cambridge, Mass. To learn more, visit www.ironwoodpharma.com.
Ironwood Pharmaceuticals, Inc.
Media Relations
Lisa
Buffington, 617-374-5103
Vice President, Corporate Communications
lbuffington@ironwoodpharma.com
or
Investor
Relations
Meredith Kaya, 617-374-5082
Associate Director,
Investor Relations
mkaya@ironwoodpharma.com
Source: Ironwood Pharmaceuticals, Inc.
News Provided by Acquire Media